CN112426450A - Eucalyptus globulus Labill extract, preparation method of pharmaceutical composition of Eucalyptus globulus Labill extract and antimalarial application of Eucalyptus globulus Labill extract - Google Patents
Eucalyptus globulus Labill extract, preparation method of pharmaceutical composition of Eucalyptus globulus Labill extract and antimalarial application of Eucalyptus globulus Labill extract Download PDFInfo
- Publication number
- CN112426450A CN112426450A CN202011557287.XA CN202011557287A CN112426450A CN 112426450 A CN112426450 A CN 112426450A CN 202011557287 A CN202011557287 A CN 202011557287A CN 112426450 A CN112426450 A CN 112426450A
- Authority
- CN
- China
- Prior art keywords
- extract
- eucalyptus globulus
- globulus labill
- preparation
- leaves
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a eucalyptus globulus labill extract and a preparation method and application of a pharmaceutical composition thereof, belonging to the pharmaceutical field of traditional Chinese medicines and natural medicines. The preparation method of the antimalarial drug taking the extract of the invention as an active component comprises the steps of taking dry overground parts or branches and leaves of eucalyptus globulus, crushing the dry overground parts or branches and leaves into 30 meshes, and extracting the crushed dry overground parts or branches and leaves with organic solvent petroleum ether, chloroform, ethyl acetate, acetone, methanol, ethanol or water. The application of the eucalyptus globulus labill extract in preparing the antimalarial agent comprises the following steps: preferably, the antimalarial activity is obtained by applying the composition to a substrate or a population in an amount of 0.01-30 g, optionally in combination with a carrier and/or vehicle. The invention expands the medicinal indications of the eucalyptus globulus and improves the medicinal value of the eucalyptus globulus.
Description
The technical field is as follows:
the invention belongs to the field of pharmacy of traditional Chinese medicines and natural medicines, and particularly relates to a preparation method of a eucalyptus globulus labill extract, a medicinal composition taking the extract as an active ingredient, and application of the extract in an antimalarial agent.
Technical background:
eucalyptus globulus (A) and (B)Eucalyptus globulusLabill) is Eucalyptus of Myrtaceae (Myrtaceae) ((R)Eucalyptus) Plants, arbors; native to the islands of the Australia Tasmanian, in cooler climates. The eucalyptus globulus is introduced into Yunnan for more than one hundred years, is generally cultivated in Yunnan, is cultivated in Guangxi and Sichuan, and is optimally grown in the Yunnan and Sichuan Wenchang areas. The plant is not suitable for being planted in low altitude and high temperature areas, and can resist low temperature below zero; the growth is rapid, and the method is a better greening and timber tree species. The wood has strong corrosion resistance and is suitable for shipbuilding and wharf; flowers are honey-source plants; the leaves and twigs can provide aromatic oil for medicinal use, and can diminish inflammation, sterilize, invigorate stomach, eliminate phlegm, dispel wind and astringe; the bark contains tanning material. In recent years, hundreds of chemical components such as phloroglucinol derivatives, flavonoids, triterpenes and the like are found in the fruits, leaves and stem bark of eucalyptus globulus. Modern pharmacological research shows that the chemical components in the eucalyptus globulus have various biological activities of resisting bacteria, resisting virus, resisting tumor, resisting oxidation, reducing blood sugar and the likeChinese herbal medicine, 2015, 46(6): 923-931). At present, no preparation method of the eucalyptus globulus labill extract, a medicinal composition taking the extract as an active ingredient and a report of the application of the extract in malaria resistance are found at home and abroad.
The invention content is as follows:
the invention aims to provide a preparation method of a eucalyptus globulus labill extract, a pharmaceutical composition taking the eucalyptus globulus labill extract as an active ingredient, and application of the eucalyptus globulus labill extract in preparation of an antimalarial agent.
The above object of the present invention is achieved by the following technical solutions:
a method for preparing Eucalyptus globulus Labill extract comprises collecting dry aerial parts or branches and leaves of Eucalyptus globulus Labill, pulverizing to 30 mesh, extracting with organic solvent such as petroleum ether, chloroform, ethyl acetate, acetone, methanol, ethanol or water at room temperature for 12-48 hr for 2-5 times, mixing extractive solutions, and concentrating to obtain extract. Or drying aerial parts or branches and leaves of Eucalyptus globulus Labill, pulverizing to 30 mesh, and extracting with organic solvent such as petroleum ether, chloroform, ethyl acetate, acetone, methanol, ethanol or water at 80-120 deg.CoC stripReflux-extracting for 2-5 times (each for 2-8 hr), mixing extractive solutions, and concentrating to obtain extract. During soaking or hot reflux, ultrasonic or microwave extraction may be adopted, and the solvent amount is 5-25 times of the weight of the soaked medicine residue.
An antimalarial agent comprises Eucalyptus globulus Labill extract and conventional adjuvant.
A pharmaceutical composition comprises a therapeutically effective amount of Eucalyptus globulus Labill extract and a pharmaceutically acceptable carrier.
Application of Eucalyptus globulus Labill extract in preparing antimalarial agent is provided.
The invention relates to a pharmaceutical composition for resisting malaria, which contains eucalyptus globulus labill extract and a pharmaceutically acceptable carrier.
The pharmaceutically acceptable carrier in the pharmaceutical composition of the invention refers to a conventional pharmaceutical carrier in the pharmaceutical field. The eucalyptus globulus labill extract of the present invention can be administered in the form of a composition to a patient in need of such treatment by oral, nasal inhalation, rectal or parenteral administration. For oral administration, it can be made into conventional solid preparations such as tablet, powder, granule, capsule, etc., and liquid preparations such as oil suspension, syrup, elixir, etc.; for parenteral administration, it can be made into solution for injection, etc. Preferred forms are tablets, capsules and injections.
Various dosage forms of the pharmaceutical composition of the present invention can be prepared according to conventional production methods in the pharmaceutical field. For example, the active ingredient may be combined with one or more carriers and then formulated into the desired dosage form.
The pharmaceutical compositions of the present invention preferably contain 0.1% to 99.5% by weight of the active ingredient, most preferably 0.5% to 95% by weight of the active ingredient.
The amount of the eucalyptus globulus labill extract to be administered may vary depending on the route of administration, age, weight of the patient, type and severity of the disease to be treated, etc., and the daily dose thereof may be 0.1 to 100 mg/kg of body weight, preferably 0.5 to 50 mg/kg of body weight. One or more administrations may be carried out.
The eucalyptus globulus labill extract of the present invention shows a superior antimalarial activity.
The invention screens the anti-malarial activity of the eucalyptus globulus labill extract, and the eucalyptus globulus labill extract shows better anti-malarial activity. In antimalarial applications, the Eucalyptus globulus Labill extract is applied to a substrate or a population in an amount ranging from 0.01 to 30 g, preferably from 0.03 to 10 g, optionally in combination with a carrier and/or vehicle.
The specific implementation mode is as follows:
the following examples are provided to further illustrate the essence of the present invention, which will enable a person skilled in the art to more fully understand the invention, but are not intended to limit the invention in any way.
Example 1:
the preparation of the eucalyptus globulus extract comprises the following steps:
collecting 132 g of dry branches and leaves of Eucalyptus globulus Labill, pulverizing to 30 mesh, adding 75% ethanol at 95%oExtracting under reflux for 3 times (2 hr each time) under C condition, mixing extractive solutions, and concentrating under reduced pressure to obtain extract 36.2 g with extraction rate of 27.4%.
Example 2:
the antimalarial activity of the extract of the invention is detected:
adopting an international 4-day inhibition experiment method, 1 × 10 percent of the total amount of the active ingredients is inoculated into the abdominal cavity of each mouse7Inoculating plasmodium into erythrocyte, administering intragastrically after 3 hr, and administering once every 24 hr for 4 days (day of inoculation is D)0The next day is D1And so on) at day 5 (D)4) The tail vein was bled, filmed, fixed with methanol, stained by mixed staining with Wright-Giemsa (Wright-Giemsa), and observed under a 10 × 100 microscope under oil microscope. If no plasmodium aneuploidy is found after randomly checking 50 visual fields, the judgment is negative, 5 visual fields are randomly counted on a positive blood film sheet, the total number of red blood cells is not less than 1000, and then the plasmodium inhibition rate is calculated according to the following formula.
Plasmodium infection rate (%). The total number of erythrocytes/erythrocytes x 100% that infected plasmodium
Plasmodium inhibition (%) (mean control mean infection ‒ sample group mean infection)/control mean infection ] × 100%
The activity data are shown in Table 1.
TABLE 1Antimalarial Activity data of Eucalyptus globulus Labill extract: (n = 4）
Claims (7)
1. A preparation method of a eucalyptus globulus labill extract is characterized in that the overground part or branch and leaf of a eucalyptus globulus labill plant is directly extracted by using an organic solvent petroleum ether or chloroform or ethyl acetate or acetone or methanol or ethanol or water through cold immersion or hot reflux to obtain an extracting solution, and the extracting solution is concentrated and dried to obtain the eucalyptus globulus labill extract.
2. The method for preparing the extract according to claim 1, wherein the above-ground parts or branches and leaves of the Eucalyptus globulus Labill are dried, pulverized to 30 mesh, extracted with organic solvent petroleum ether or chloroform or ethyl acetate or acetone or methanol or ethanol or water at room temperature, and the extract is concentrated to obtain an extract.
3. The method for preparing the extract according to claim 1, wherein the above-ground parts or branches and leaves of the Eucalyptus globulus Labill are dried, pulverized to 30 mesh, extracted by organic solvent petroleum ether or chloroform or ethyl acetate or acetone or methanol or ethanol under reflux, and the extract is concentrated to obtain extract.
4. The method according to claims 2 and 3, wherein the soaking or thermal refluxing is assisted by ultrasonic or microwave extraction, and the amount of solvent used each time is 5-25 times the weight of the soaked herb residue.
5. A pharmaceutical composition comprising a therapeutically effective amount of the extract of claim 1 and a pharmaceutically acceptable carrier.
6. An antimalarial agent comprising the extract of claim 1 and conventional adjuvants.
7. Use of the extract of claim 1 for the preparation of an antimalarial agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011557287.XA CN112426450A (en) | 2020-12-25 | 2020-12-25 | Eucalyptus globulus Labill extract, preparation method of pharmaceutical composition of Eucalyptus globulus Labill extract and antimalarial application of Eucalyptus globulus Labill extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011557287.XA CN112426450A (en) | 2020-12-25 | 2020-12-25 | Eucalyptus globulus Labill extract, preparation method of pharmaceutical composition of Eucalyptus globulus Labill extract and antimalarial application of Eucalyptus globulus Labill extract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112426450A true CN112426450A (en) | 2021-03-02 |
Family
ID=74696983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011557287.XA Pending CN112426450A (en) | 2020-12-25 | 2020-12-25 | Eucalyptus globulus Labill extract, preparation method of pharmaceutical composition of Eucalyptus globulus Labill extract and antimalarial application of Eucalyptus globulus Labill extract |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112426450A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115869356A (en) * | 2023-01-31 | 2023-03-31 | 大理大学 | Preparation of barb active part with anti-trichina medicine |
-
2020
- 2020-12-25 CN CN202011557287.XA patent/CN112426450A/en active Pending
Non-Patent Citations (3)
| Title |
|---|
| 唐静等: "植物提取物、碳酸钠和碳酸氢钠室内对杨树溃疡病菌生长的抑制作用", 《植物病理学报》 * |
| 易磊编著: "《妙用本草良方》", 31 March 2017, 中医古籍出版社 * |
| 钱金栿等编著: "《大理苍山植物药物志》", 31 March 2016, 云南科技出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115869356A (en) * | 2023-01-31 | 2023-03-31 | 大理大学 | Preparation of barb active part with anti-trichina medicine |
| CN115869356B (en) * | 2023-01-31 | 2023-12-22 | 大理大学 | Preparation of barb active site for anti-trichina medicine |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101185692B (en) | Nauclea officinalis extract and preparation and use thereof | |
| CN109912551A (en) | Sesquiterpene eudesmanolide class compound and its pharmaceutical composition and preparation method and application | |
| KR20110128385A (en) | The herb medicine composition material and the manufacturing process for pimple skin-improvement uses by midam cheonggyeolan | |
| CN112426450A (en) | Eucalyptus globulus Labill extract, preparation method of pharmaceutical composition of Eucalyptus globulus Labill extract and antimalarial application of Eucalyptus globulus Labill extract | |
| CN112402479A (en) | Rhododendron rubrum extract, preparation method of pharmaceutical composition of rhododendron rubrum extract and antimalarial application of rhododendron rubrum extract | |
| CN112426446A (en) | Sophora japonica extract, preparation method of pharmaceutical composition of extract and antimalarial application of extract | |
| CN109498663A (en) | Nine primary and secondary genus plants extracts and its pharmaceutical composition preparation method and antimalarial purposes | |
| CN103816210A (en) | Pueraria lobata extract and application thereof | |
| Aziz et al. | In vivo pharmacological investigation of Mimosa pudica L | |
| CN112494526A (en) | Rhus chinensis extract, and preparation method and application of pharmaceutical composition thereof | |
| CN112472778A (en) | Ivory root extract, preparation method of pharmaceutical composition of ivory root extract and antimalarial application of ivory root extract | |
| KR100248942B1 (en) | Saururus extract with anticancer effect and process for preparation thereof | |
| CN109806304A (en) | The preparation method of three leaf raspberry plant extracts and its pharmaceutical composition and anti-trichina purposes | |
| CN108586626A (en) | A kind of preparation method and applications of radix tetrastigme oligosaccharide | |
| CN113057974A (en) | Yunnan kaki extract, its pharmaceutical composition preparation method and antimalarial application | |
| CN107082780B (en) | Alkaloid with pyrroloisoquinoline structure and preparation method and application thereof | |
| CN113318137B (en) | Preparation method of water-soluble acanthopanax powder capsule | |
| CN110305017B (en) | Noreudesmane sesquiterpenoids, and pharmaceutical composition, preparation method and application thereof | |
| CN109718263A (en) | Megarpaea delavayi Franch genus plants extract and its pharmaceutical composition preparation method and application | |
| CN109758493B (en) | Application of cardamine hirsute and extract thereof in preparation of drugs for preventing or treating arrhythmia | |
| CN1981832A (en) | Use of cape-jasmine extract in treatment of chronic hepatitis B | |
| CN109172675B (en) | Preparation method and application of zanthoxylum bungeanum root total lignan extract | |
| Gautam et al. | Pharmacological and Photochemical Study of Punica Granatum: A Review | |
| CN109718264A (en) | The preparation method and antimalarial purposes of bright pink wood extract and its pharmaceutical composition | |
| Du et al. | Bergenin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210302 |
|
| WD01 | Invention patent application deemed withdrawn after publication |